Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP

Jessica Escoffier, Hoi Chang Lee, Sandra Yassine, Raoudha Zouari, Guillaume Martinez, Thomas Karaouzène, Charles Coutton, Zine-eddine Kherraf, Lazhar Halouani, Chema Triki, Sergey N. Savinov, Rafael Fissore, Pierre F. Ray and Christophe Arnoult

1Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland, 2Department of Veterinary and Animal Sciences and 3Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, MA 01003, USA, 4Université Grenoble Alpes, Grenoble, F-38000, Grenoble, France, 5Institut Albert Bonniot, INSERM U823, La Tronche F-38700, France, 6Polyclinique les Jasmins, Centre d’Aide Médicale à la Procréation, Centre Urbain Nord, 1003 Tunis, Tunisia, 7CHU de Grenoble, UF de Génétique Chromosomique, Grenoble F-38000, France, 8Clinique Hannibal, Centre d’AMP, les berges du lac, 1053 Tunis, Tunisia, 9Laboratoire TIMC-IMAG, UMR CNRS 5525, Grenoble F-38000, France and 10CHU de Grenoble, UF de Biochimie et Génétique Moléculaire, Grenoble F-38000, France

*To whom correspondence should be addressed at: Faculté de Médecine et de Pharmacie, Équipe ‘Génétique, Epigénétique et Thérapies de l’Infertilité’, Bâtiment Jean Roget – 3 étage, Pièce 311, Place du Cdt NAL – Domaine de la Merci, 38700 La Tronche, France. Tel: +33 476637408; Email: christophe.arnoult@ujf-grenoble.fr

Abstract

In mammals, sperm–oocyte fusion initiates Ca²⁺ oscillations leading to a series of events called oocyte activation, which is the first stage of embryo development. Ca²⁺ signaling is elicited by the delivery of an oocyte-activating factor by the sperm. A sperm-specific phospholipase C (PLCZ1) has emerged as the likely candidate to induce oocyte activation. Recently, PAWP, a sperm-born tryptophan domain-binding protein coded by WBP2NL, was proposed to serve the same purpose. Here, we studied two infertile brothers exhibiting normal sperm morphology but complete fertilization failure after intracytoplasmic sperm injection. Whole exonic sequencing evidenced a missense homozygous mutation in PLCZ1, c.1465A>T; p.Ile489Phe, converting Ile 489 into Phe. We showed the mutation is deleterious, leading to the absence of the protein in sperm, mislocalization of the protein when injected in mouse GV and MII oocytes, highly abnormal Ca²⁺ transients and early embryonic arrest. Altogether these alterations are consistent with our patients’ sperm inability to induce oocyte activation and initiate embryo development. In contrast, no deleterious variants were identified in WBP2NL and PAWP presented normal expression and localization. Overall we demonstrate in humans, the absence of PLCZ1 alone is sufficient to prevent oocyte activation irrespective of the presence of
PAWP. Additionally, it is the first variant located in the C2 domain of PLCZ1, a domain involved in targeting proteins to cell membranes. This opens the door to structure-function studies to identify the conserved amino acids of the C2 domain that regulate the targeting of PLCZ1 and its selectivity for its lipid substrate(s).

**Introduction**

Increases in the intracellular concentration of free calcium (Ca²⁺) was demonstrated to be a sufficient and necessary stimulus to trigger oocyte activation and embryo development in all species studied to date (1). This finding along with subsequent confirmatory studies (2) stimulated interest to elucidate the signaling cascade responsible for Ca²⁺ release at fertilization. In 1990, studies showed that a soluble component of mammalian sperm extracts, aptly named the sperm factor, was sufficient to induce oocyte activation and replicate the periodical Ca²⁺ oscillations, known as Ca²⁺ oscillations, which are a hallmark of mammalian fertilization (3,4). PLCZ1 was later identified as the candidate molecule to be the active factor in sperm responsible for the oscillations (5,6). Research from several laboratories confirmed the unique properties of PLCZ1 to induce Ca²⁺ oscillations in oocytes as well as the association of its absence with infertility (7–12). However, the inability thus far to obtain a PLCZ1 KO animal model capable of producing mature sperm (13) has prevented assigning to this molecule the exclusive role for oocyte activation, while leaving open the possibility that other sperm factors may be required (14). Toward that end, PAWP has been proposed as an alternative or complementary pathway for oocyte activation based on findings that injection of recombinant PAWP induced oscillations comparable to those of fertilization (15,16). The relationship between the proposed function of PAWP and its structure is not yet understood. PAWP displays sequence homology to WW domain-binding protein 2 (WBP2) in its N terminal end and a variable number of PPXY motifs (one in human, six in mouse) in its C-terminal end, a motif known to interact with WW domain. Moreover, the C terminal end contains an unidentified repeated motif (YGKPPP) (17). It is presently unknown, however, how these motifs may engage the oocyte’s signaling machinery to induce Ca²⁺ oscillations. In this vein, attempts to replicate those studies in mouse oocytes failed (18,19), which raised concerns regarding the importance of PAWP in fertilization. However, its action in human oocyte activation was not formally ruled out, especially as numerous studies have shown that testis and reproductive tissues evolve faster than their somatic counterparts, raising concerns regarding the importance of PAWP in fertilization. The inability thus far to obtain a PLCZ1 KO animal model capable of producing mature sperm (13) has prevented assigning to this molecule the exclusive role for oocyte activation, while leaving open the possibility that other sperm factors may be required (14). Toward that end, PAWP has been proposed as an alternative or complementary pathway for oocyte activation based on findings that injection of recombinant PAWP induced oscillations comparable to those of fertilization (15,16). The relationship between the proposed function of PAWP and its structure is not yet understood. PAWP displays sequence homology to WW domain-binding protein 2 (WBP2) in its N terminal end and a variable number of PPXY motifs (one in human, six in mouse) in its C-terminal end, a motif known to interact with WW domain. Moreover, the C terminal end contains an unidentified repeated motif (YGKPPP) (17). It is presently unknown, however, how these motifs may engage the oocyte’s signaling machinery to induce Ca²⁺ oscillations. In this vein, attempts to replicate those studies in mouse oocytes failed (18,19), which raised concerns regarding the importance of PAWP in fertilization. However, its action in human oocyte activation was not formally ruled out, especially as numerous studies have shown that testis and reproductive tissues evolve faster than their somatic counterparts, raising concerns regarding the importance of PAWP in fertilization. The inability thus far to obtain a PLCZ1 KO animal model capable of producing mature sperm (13) has prevented assigning to this molecule the exclusive role for oocyte activation, while leaving open the possibility that other sperm factors may be required (14). Toward that end, PAWP has been proposed as an alternative or complementary pathway for oocyte activation based on findings that injection of recombinant PAWP induced oscillations comparable to those of fertilization (15,16). The relationship between the proposed function of PAWP and its structure is not yet understood. PAWP displays sequence homology to WW domain-binding protein 2 (WBP2) in its N terminal end and a variable number of PPXY motifs (one in human, six in mouse) in its C-terminal end, a motif known to interact with WW domain. Moreover, the C terminal end contains an unidentified repeated motif (YGKPPP) (17). It is presently unknown, however, how these motifs may engage the oocyte’s signaling machinery to induce Ca²⁺ oscillations. In this vein, attempts to replicate those studies in mouse oocytes failed (18,19), which raised concerns regarding the importance of PAWP in fertilization. However, its action in human oocyte activation was not formally ruled out, especially as numerous studies have shown that testis and reproductive tissues evolve faster than their somatic counterparts, raising concerns regarding the importance of PAWP in fertilization.

Here, we studied two infertile brothers showing complete fertilization failure after intracytoplasmic sperm injection (ICSI). Whole-exome sequencing enabled us to find a missense homozygous mutation in PLCZ1, c.1465A>T; p.Ile489Phe, converting an Ile at position 489 into a Phe (Ile489Phe) (Fig.3A). No other homozygous variants were identified in the C2 domain of the enzyme, an important domain targeting proteins to lipidic membranes, opening the door for better structure-function analysis of PLCZ1 and of other proteins carrying this domain.

**Results**

**Patients’ description: medical records and spermatocytogram**

Two Tunisians brothers and their respective wives sought medical advice from infertility clinic in Tunis between 2011 and 2014 after unsuccessful attempts for a full year to conceive a pregnancy. The brothers were born from first cousin parents and have one fertile brother with children conceived spontaneously and two fertile sisters. The morphology of patients’ sperm was assessed with Shorr staining (Fig. 1A) and sperm parameters were well above the low reference limits set by the WHO guidelines (21), although Patient 1 (P1) had higher than average number of sperm with acrosome defects (Table 1). To investigate this in more detail, we examined the presence and morphology of the acrosome by IF using an anti-acrosin antibody. We found that the acrosome presented a normal shape in ∼50% of the brothers’ sperm (Fig. 1D and E). While not examined, we estimate that the absence of staining on the other half is due to a premature acrosome reaction rather than to an abnormal acrosome biogenesis, as the shape of the sperm heads was normal and not globozoospermic (Fig. 1). We also assessed DNA quality using three different methods: chromocyon A3, aniline blue (AB) and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick-end labeling (TUNEL), which allowed evaluation of DNA protamination, histone content and DNA fragmentation, respectively. The percentages of positive sperm were higher in patients than in fertile controls, but all values were ∼20% (Fig. 2) and remained below abnormal thresholds defined by several studies (22–24). Remarkably, although these sperm parameters were compatible with spontaneous conception, for both brothers the clinical outcomes following assisted reproduction technologies procedures was oocyte activation failure (OAF); P1 had two unsuccessful attempts of artificial insemination and then sperm from both patients were used for ICSI. In total, 3 ICSI cycles were carried out and 20 MII oocytes were injected, but none showed signs of oocyte activation (Table 2).

**Whole-exome sequencing identified a homozygous missense mutation in PLCZ1**

Since both brothers were married to unrelated women, we excluded the possibility of a female factor and focused our research on the brothers. Given the family history of consanguinity, we postulated that this infertility was caused by a homozygous mutation. We, therefore, proceeded to whole-exome sequencing to identify a possible genetic defect(s) that could explain the observed OAF. After exclusion of frequent variants, only four homozygous variants were identified in both brothers (Table 3). Three variants, located in EPS8 (also known as DFNB102), RP11-1021N1.1 and LKAAEAR1 (also known as C20orf201), had no expected deleterious effect. The fourth variant was a missense mutation on PLCZ1, c.1465A>T located in exon 13 (NM_033123.3), changing an Ile at position 489 into a Phe (Ile489Phe) (Fig. 3A). No other
variants were identified in the PLCZ1-coding sequence, UTR regions or close intronic regions. Given that PLCZ1 has been suggested to be necessary for oocyte activation in mammals, this mutation could underlie the patients’ phenotype. Sanger sequencing confirmed the homozygous mutation for both infertile brothers and showed that the third fertile brother was heterozygous (Fig. 3B). The c.1465A>T variant was absent from over 60,000 individuals described in the ExAC database (exac.broadinstitute.org), which confirms it is not a polymorphism and that missense variations occurring at this localization would likely cause negative selection throughout evolution. Moreover, we found Ile489 to be well conserved throughout evolution (Fig. 3C), suggesting that this mutation could be deleterious.

**Deleterious effects of the identified mutation**

In order to assess the impact of the mutation, PLCZ1 expression and localization were first studied on sperm from both patients (Fig. 4A). We used an antibody targeting human PLCZ1 (anti-hPLCZ1). This antibody has been published and used in three
previous publications and the respective western blots showed remarkably specificity (7,11,25). Whereas the sperm of fertile patients showed a band of strong staining on the post-acrosomal area and more diffuse staining over the acrosome (Fig. 4A1, inset), there was no staining detectable in the patients’ sperm, except for a few of them showing a faint punctuate staining over the acrosome (Fig. 4A2, inset), suggesting that the mutant PLCZ1 was absent or present at very low concentrations. The absence of PLCZ1 in the patients’ sperm was confirmed by WB, where a single band at the expected MW of PLCZ1 was noticeable in the control lane, whereas there was no reactivity in the patients’ lanes (Fig. 4B), although similar sperm number were loaded per lane (Fig. 4C). These results suggest that during spermatogenesis Ile489Phe PLCZ1 displays defects in stability, trafficking and/or anchoring, which prevent its presence in mature sperm. To examine these possibilities, cRNAs of human WT and Ile489Phe Venus-tagged PLCZ1 were injected into mouse GV oocytes, which were maintained arrested at the GV stage with IBMX; this was done to ascertain the distribution of the enzyme independently of the stage of the cell cycle. It is noteworthy that is presently unknown how PLCZ1 distribution is regulated in oocytes, although unlike other PLCs (26), it does not appear to localize to the plasma membrane (27), where its substrate, is found. In agreement with this remark, WT PLCZ1 exhibited a homogeneous distribution in the ooplasm of GV oocytes that partly overlapped with distribution of the endoplasmic reticulum (ER), which was marked by ER-DsRed (Fig. 5A). In contrast, Ile489Phe PLCZ1 displayed an uneven distribution characterized by large patches near the nucleus and decreased peripheral localization (Fig. 5B). Furthermore, Ile489Phe PLCZ1 distribution did not overlap with the ER. These results suggest that the mutation does not affect the stability of PLCZ1, although its trafficking and/or anchoring properties were clearly altered. To further test the latter, we took advantage of the fact that following fertilization, Plc11 is translocated into the pronuclei (PN) (28,29). The sequestration of P1c1 into the PNs is thought to contribute to the cessation of Ca2+ oscillations, which in the mouse closely corresponds with their formation. WT and Ile527Phe mPlc11 cRNAs [the equivalent mutation of Ile489Phe human PLCZ1 (hPLCZ1)] were injected into MII oocytes, which were activated by the oscillations initiated by the translated proteins. Following PN formation, as expected, WT mPlc11 accumulated into the PN. In contrast, following injection of Ile527Phe mPlc11 cRNA, PN formation was delayed by ~3 h, presumably due to the lower frequency of oscillations, and the mutant protein failed to localize to the PN (Fig. 5C). These results confirm that the mutation modifies PLCZ1’s anchoring and/or trafficking properties in oocytes and zygotes.

We next assessed the enzymatic activity of the mutated human (h) and mouse (m) PLCZ1s, by examining Ca2+ responses elicited by the injection of their respective cRNAs into mouse MII oocytes. WT hPLCZ1 cRNA (0.001 μg/μl) initiated high-frequency oscillations in all injected oocytes (Fig. 6A) whereas the mutant hPLC11 cRNA failed to initiate oscillations in 14/31 oocytes (46%) or induced responses with a low frequency in 13/31 oocytes (54%) (Fig. 6B). Furthermore, the enzymatic activity of the mutant versus WT hPLCZ1 was reduced irrespective of the concentrations of cRNA injected (Fig. 6C). These results suggest that possible trace amounts of hPLCZ1 are likely not sufficient to activate oocytes. To confirm this hypothesis, both WT and mutant cRNAs were injected into mouse oocytes, and the development of parthenogenetic embryos was followed by evaluating the rates of PN formation, cleavage to the two-cell stage and blastocysts. Following injection of WT hPLCZ1 64.6% of the oocytes showed signs of activation (2PN) and 35% reached the blastocyst stage. In contrast, Ile489Phe hPLCZ1, as Ca2+ responses triggered by the mIle527Phe mutant cRNA, initiated high-frequency oscillations in 17/31 oocytes (54%) (Fig. 6D). These results were obtained with the mutant mPlc11, as Ca2+ responses triggered by the mIle527Phe mutant were weaker than those observed with WT Plc11, showing longer lag time and reduced frequency (Fig. 7A, B). Consistent with this, the timing of PN formation was delayed and the percentages of zygotes reaching the 2PN stage at 6 and 10 h post-insemination

<table>
<thead>
<tr>
<th>Table 1. Semen parameters and spermatoctyogram of P1 and P2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semen parameters</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Semen volume (ml)</td>
</tr>
<tr>
<td>Sperm concentration (106/ml)</td>
</tr>
<tr>
<td>Total motility 1 h (%)</td>
</tr>
<tr>
<td>Vitality (%)</td>
</tr>
<tr>
<td>Normal spermatozoa (%)</td>
</tr>
<tr>
<td>Anomalies of the flagella (%)</td>
</tr>
<tr>
<td>Abnormal acrosome (%)</td>
</tr>
<tr>
<td>Other anomalies of the head (%)</td>
</tr>
<tr>
<td>Multiple anomalies index (%)</td>
</tr>
</tbody>
</table>

Values are the average of two separate analyses.

Figure 2. Assessment of nucleus compaction and DNA breaks of sperm from OAF patients. (A) Histones content of sperm was assessed using the AB test. The histogram shows the percentage of stained sperm in samples from control (n = 5 ± SD) and patients (n = 1). (B) Protamination of sperm was evaluated using the chromomycin A3 test, and results are displayed in the histogram, which shows the percentage of stained sperm in control (n = 5 ± SD) and patients’ (n = 1) samples. (C) The histogram of DNA fragmentation analysis with TUNEL assay showing the level of TUNEL-positive sperm in control (n = 5 ± SD) and patients’ (n = 1) samples.
Table 2. ICSI outcomes following stimulation cycles with sperm from P1 and P2

<table>
<thead>
<tr>
<th>Patient and procedure</th>
<th>Years</th>
<th>No. of follicles (n)</th>
<th>No. of abnormal oocytes (GV, M1, atretic) (n)</th>
<th>No. of mature oocytes injected (n)</th>
<th>No. of 2PN oocytes (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1 ICSI—Jasmin clinic</td>
<td>2011</td>
<td>9</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>P1 ICSI—Jasmin clinic</td>
<td>2012</td>
<td>9</td>
<td>2</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>P2 ICSI—Jasmin clinic</td>
<td>2012</td>
<td>14</td>
<td>6</td>
<td>8</td>
<td>0</td>
</tr>
</tbody>
</table>

Number (n). P1 and P2 are brothers.

Table 3. List of common homozygous variants present in P1 and P2

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant coordinates</th>
<th>Transcript</th>
<th>cDNA variation</th>
<th>Amino acid variation</th>
<th>Prediction</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLCZ1</td>
<td>chr12:168411149, T&gt;A</td>
<td>NM_033123.3</td>
<td>c.1465A&gt;T</td>
<td>p.Ile489Phe</td>
<td>Damaging</td>
</tr>
<tr>
<td>EPS8</td>
<td>chr12:15776164, A&gt;C</td>
<td>NM_004447.5</td>
<td>c.286T&gt;C</td>
<td>p.Tyr96His</td>
<td>Benign</td>
</tr>
<tr>
<td>RP11-1021N1.1</td>
<td>chr16:15528278, T&gt;C</td>
<td>ENST00000568222</td>
<td>c.256T&gt;G</td>
<td>p.Tyr96His</td>
<td>Benign</td>
</tr>
</tbody>
</table>

Coordinates of all variations are based on the UCSC GRCh37/hg19 assembly.

The Ile489Phe mutation alters the conformation of the C2 domain

To assess the possible impact of the mutation on the structure of hPLCZ1, a 3D structure of hPLCZ1 was modeled from the crystallographic structure of PLCX1 (42% identity and 59% homology). The model shows that Ile489 is at the interface of the EF hand and C2 domains, and it appears as being too far from the catalytic domain to directly affect its function (Fig. 8A). Using molecular dynamics simulations of the hPLCZ1 and hPLCZ1-Ile489Phe models, we observed that the larger size of Phe over Ile (203 versus 169 Å²), which requires more accommodating space (Supplementary Material, Fig. S1), results first in a displacement of its intra-domain neighbors (Y582, F601, Y603 and R487) and second in establishing a unique inter-domain hydrophobic contact with I76 from the proximal EF-hand 2 helix (Fig. 8B and C). The first notable outcome of these perturbations is that causes a significant shift of the EF2 domain toward the C2 domain (12.2 versus 10.7 Å for CαI76 from the proximal EF-hand 2 helix (Fig. 8B and C). The second notable outcome is the formation in the C2 domain of an aromatic-rich concave-like sub-site capable of associating with lipophilic molecules or protein surfaces (Fig. 8D). Because EF hands have been shown to be important for both PLCZ1 anchoring on phospholipids and its nuclear translocation (30,31), this unique new inter-domains interaction in the mutant enzyme could support the observed deleterious effects of the mutation.

Normal PAWP expression in patients with Ile489Phe PLCZ1 mutation

We next examined the sequence of WBP2NL, which encodes for PAWP. Analysis of exome data from P1 and P2 did not reveal any sequence variation in the WBP2NL-coding sequence, UTR regions or close intronic regions indicating that P1 and P2 should produce a fully functional PAWP protein. Because exome sequencing only allows covering 80–90% of all targeted sequences, WBP2NL coverage was verified: all exons and exon borders for both patients was at least 40×, which unambiguously confirmed the absence of deleterious variants in WBP2NL in the patients (Supplementary Material, Fig. S3). Consistent with these results, we confirmed by WB normal expression of PAWP (Fig. 9A) using extracts of sperm from patients and a fertile control prepared with similar number of sperm (Fig. 9B). We also examined PAWP localization by IF and in agreement with previous reports, PAWP reactivity appeared as a compact band around the equatorial/post-acrosomal area in the sperm of a control fertile human (Fig. 9C) as well as in the sperm of both patients (Fig. 9C2). Altogether, these results show that PAWP is unable to support activation of human oocytes when PLCZ1 is absent and/or non-functional.

To extend these results, we examined the sperm from Dpy19I2 KO males. Dpy19I2 homozygous KO male mice are infertile, they have round-headed acrosomeless spermatozoa, which fail to induce oocyte activation following ICSI due to loss of Plcz1 (11,32). Here, we show by WB that PAWP expression is normal in these round-headed sperm (Supplementary Material, Fig. S4), demonstrating that its presence is not sufficient to trigger oocyte activation when ICSI is performed. Therefore, it appears the presence of PAWP is incapable of rescuing the lack of activation caused by the absence of PLCZ1 expression in human or mouse sperm.

Discussion

Infertility and Ile489Phe PLCZ1

Herein, we have used whole-exome sequencing to identify a homozygous missense mutation in PLCZ1 in two infertile brothers presenting OAF. The mutation led to an almost complete disappearance of the protein in the patients’ sperm and based on the targeting and/or anchoring defects observed following injection of cRNAs into oocytes, we estimate it hampers the retention of PLCZ1 in mature sperm. During spermatogenesis, as in all cells, proteins are synthesized in the reticulum and targeted to their final location according to their function. However, the
endoplasmic reticulum (ER) and all components necessary for proteins synthesis are eventually discarded at the end of the spermatozoon differentiation, leading to the release of a giant anucleate vesicle known as the residual body (33). We have previously shown that PLCZ1 is specifically located in the perinuclear theca in the vicinity of the inner acrosomal membrane of mature human sperm (11). The absence of PLCZ1 in the patients’ sperm suggests that the mutation may prevent PLCZ1 from reaching and attaching to the perinuclear theca/inner acrosomal membrane, which renders it susceptible to disposal through the residual body. It is worth noting that PLCZ1 is also absent in globozoospermic sperm, which display defects in the perinuclear theca region and lack the acrosome vesicle (11). Moreover, we showed that the mutant protein had a strongly impaired ability to produce inositol 1,4,5-trisphosphate (IP3), as witnessed by the failure to induce Ca2+ oscillations and to sustain normal embryonic development, contrary to the WT protein. The OAF of these patients is thus due to the dramatic decrease of both PLCZ1 concentration and IP3 production.

**Ile489Phe PLCZ1 and function of the C2 domain of PLCZ1**

PLCs belong to a large family of enzymes able to bind to lipids in membranes where they hydrolyze specific phospholipids, mostly PIP2. Several classical molecular domains are found in PLCs, including two catalytic domains, called X and Y, and working in tandem, lipid-binding domains such as PH and C2 and EF-hand domains, which are Ca2+-dependent domains (34). PLCZ1 is the shortest PLC and contains only four domains: four EF hands, the XY catalytic tandem and a C2 domain (Fig. 3) and the lack of a PH domain favor its more widespread distribution in the ooplasm. The C2 domain, which is the site of the homozygous mutation in our patients, is a lipid-binding domain shared by more than 100 human proteins. Originally, C2 domains were

---

**Figure 3.** The Ile489Phe mutation is located in the C2 domain of PLCZ1. (A) Schematic representation of the exonic structure of human PLCZ1 cDNA sequence and corresponding functional domains of PLCZ1 (http://www.uniprot.org/uniprot/Q86YW0). The first coding exon is exon 2 (exon sizes are not to scale). The mutation c.1465A>T; p.Ile489Phe (NM_033123.3) is located in exon 13 and changes Isoleucine 489 located in the C2 domain into a phenylalanine. (B) The presence of the identified variation c.1465A>T; p.Ile489Phe (NM_033123.3) was verified by Sanger sequencing of PLCZ1 exon 13. Electropherogram of PLCZ1 exon 13 showing the mutated sequence and sequence obtained from a control individual. The two infertile brothers carried a homozygous missense mutation (p.Ile489Phe) in PLCZ1 exon 13 whereas the fertile brother harbors the mutation in a heterozygous state. (C) The mutation is located in a cluster of 15 highly conserved amino acids.
shown to bind membranes in a Ca\textsuperscript{2+}-dependent manner (35,36). Crystallographic studies have shown that C2 domains have a common fold of conserved eight-stranded antiparallel \( \beta \)-sandwich (37,38), which, according to our modeling studies, are also present in PLCZ1 (Fig. 8). There are two areas important for lipid binding in this domain, which are the highly variable loops between \( \beta \)-strands and a cationic patch in the concave face of the \( \beta \)-sandwich that corresponds to \( \beta_3 \)- and \( \beta_4 \)-strands (39). However, the sequence conservation among C2 domains is low and a significant number of C2 domains with little to no Ca\textsuperscript{2+} affinity have been identified, which is the case for the C2 domain of PLCZ1 (39). Moreover, some C2 domains have low-membrane affinity and are involved in protein–protein interaction. Although it has been shown that PLCZ1 deleted of the full C2 domain does not produce Ca\textsuperscript{2+} oscillations, demonstrating thus that the C2 domain of PLCZ1 is necessary for the overall enzymatic activity (30,40), its molecular function remains uncharacterized so far. The Ile489Phe mutation, which is located in the \( \beta_1 \)-strand of the C2 domain, opens the door for structure–function studies to define how the conserved amino acids on the C2 domain are involved in protein targeting and selectivity for lipid substrate(s).

Our results, following injection of PLCZ1 cRNAs into oocytes, have showed that the WT protein was distributed evenly in the ooplasm and its area of distribution largely overlapped that of the ER, whereas the Ile489Phe PLCZ1 was unevenly distributed and accumulated around the nucleus. It is worth noting that the subcellular localization of C2-domain containing proteins is controlled by the lipid selectivity of the C2 domain and it is also known that lipid selectivity is highly variable among C2 domains (39,41). For instance, PLC\( \delta \) is located in the phosphatidylyserine (PS) rich PM because its C2 domain selectively binds PS (26), whereas cPLA\( \alpha \) translocates to the perinuclear ER, which is rich in phosphatidylcholine, the target of its C2 domain (41). We can, therefore, speculate that the C2 domain of Ile489Phe PLCZ1 displays changed lipid affinity, which alters the intracellular distribution of the enzyme, and this may conspire to its retention in mature sperm and its reduced catalytic activity in oocytes. Altogether, our results suggest for the first time that the C2 domain of PLCZ1 participates in the targeting of the enzyme to lipid-containing membranes and our results demonstrate a pivotal role of a stretch of highly conserved residues in the C2 domain surrounding Ile489. It is also the first description of a functional role for residues located in the \( \beta_1 \)-strand of a C2 domain (42).

Our molecular modeling studies of WT and mutant PLCZ1 offers insights into the atomic-level perturbations caused by the Ile489Phe mutation. Dynamic simulations showed the Ile489Phe mutation is likely to induce a shift of the EF2-hand helix 1 toward C2, and given that EF2 hand is involved in binding to lipid membrane (30,31), this shift may reduce enzymatic activity. Further, the opening of a new aromatic-rich surface patch in the mutant protein capable of associating with additional hydrophobic counterparts may also alter the distribution and/or activity of the enzyme. Finally, the nuclear translocation of the mIle527Phe Plc1 is hampered, suggesting that binding to nuclear import proteins necessary for PN translocation is defective (43), which may suggest a role of C2 domain in protein–protein interactions. Therefore, by changing the structural properties of the C2 domain and its interaction with the EF-hand domains, Ile489Phe mutation is likely to modify the interactions of PLCZ1 with lipid membranes and possibly proteins, directly affecting its targeting and/or anchoring properties and enzymatic activity, all of which undermine the fertility of patients bearing this mutation.

**PLCZ1 and oocyte activation**

The function of PLCZ1 as the sperm factor has recently been challenged, and another protein, PAWP, has been proposed as an alternative candidate (15,16). Controversial results, however, have been published (18,19) and it is presently unclear how this protein is involved in human fertilization. The study of genetic diseases often provides the opportunity to better understand protein functions and our understanding of reproduction, including gametogenesis and fertilization, has benefited from the genetic characterization of several phenotypes of male and female infertilities (44). In human, a link between OAF and PLCZ1 was first reported in patients displaying abnormal expression and localization of PLCZ1 in sperm (7). However, these patients exhibited severe teratozoospermia, which raised concerns about miss-expression and/or malfunction of several proteins. Heytens et al. (8) provided the first genetic evidence linking PLCZ1 to infertility, as they found a heterozygous mutation at position 398 of the Y catalytic domain of PLCZ1 that reduced its ability to induce Ca\textsuperscript{2+} oscillations. Nevertheless, it was unclear how this heterozygous mutation could cause infertility, although, subsequently, another heterozygous mutation was found in the same patient at position 233 of the X catalytic domain, resulting in compound
heterozygosity, which reinforced the link between PLCZ1, OAF and infertility (45). Here, we show the first identified homozygous mutation of PLCZ1 leading to OAF and infertility. Importantly, it is the first exomic analysis of patients presenting OAF. We identified only four homozygous variants shared by both brothers: three of them were not expected to have any deleterious effects, whereas the fourth one was found in the PLCZ1 coding sequence. Importantly, this mutation was not associated with teratozoospermia and the numbers of normal sperm were well above the lower accepted reference values (21). Moreover, the sperm of both brothers showed only slightly reduced DNA quality, ruling this out as the cause of OAF (46,47). Altogether, these results indicate that PLCZ1 plays a direct and primary role in the activation of mammalian oocytes. It is worth noting that a Plcz1 KO animal model does not presently exist, due to an early spermatogenesis arrest in this model (13), and this absence has been used to raise doubts about the role of PLCZ1 in oocyte activation. Here, we present the first functional knock-down of PLCZ1 in human sperm without effects on spermatogenesis and the results demonstrate a required role for oocyte activation in the species. Furthermore, our results demonstrate the importance of specific residues in the C2 domain for the enzyme’s function, future studies should establish the molecular target(s) in the ooplasm and the host organelle that guide the enzyme to sites of accessible and abundant substrate, which is required to support the long-lasting oscillations that underlie egg activation in mammals.

Materials and Methods

Biological samples

Sperm were obtained following informed consent from patients consulting with the Department of fertility at Grenoble (France) or with the Clinique des Jasmins (Tunis, Tunisia) after approval by the Ethics committee of the university. In addition, all patients gave informed consent for preservation of unused sperm in the Germetheque biobank and subsequent use for studies on human fertility in accordance with the Helsinki Declaration on human experimentation. Dpy19l2 KO mice were obtained from the Mutant Mouse Regional Resource Center, University of California, Davis, CA, USA.
Exome sequencing and bioinformatics analysis

Genomic DNA was isolated from saliva using Oragen DNA extraction kit (DNAgenotech®, Ottawa, Canada). Coding regions and intron/exon boundaries were enriched using the ‘all Exon V5 kit’ (Agilent Technologies, Wokingham, UK). DNA sequencing was undertaken at the Genoscope, Evry, France, on the HiSeq 2000 from Illumina®. Sequence reads were aligned to the reference genome (hg19) using MAGIC (49). Duplicate reads and reads that mapped to multiple locations in the exome were excluded from further analysis. Positions whose sequence coverage was <10 on either the forward or reverse strand were excluded. Single-nucleotide variations and small insertions/deletions (indels) were identified and quality-filtered using in-house scripts. The most promising candidate variants were identified using an in-house bioinformatics pipeline. Variants with a minor allele frequency >5% in the NHLBI ESP6500 or in 1000 Genomes Project phase 1 data sets, or >1% in ExAC, were discarded. We also compared these variants with an in-house database of 56 control exomes obtained from subjects from the same geographic origin as our two patients (North Africa). All variants present in homozygous state in this database were excluded. We used variant effect predictor to predict the impact of the selected variants. We only retained variants impacting splice donor/acceptor or causing frameshift, intrame insertions/deletions, stop gain, stop loss or missense variants except those scored as ‘tolerated’ by SIFT (sift.jcvi.org) and as ‘benign’ by Polyphen-2 (genetics.bwh.harvard.edu/pph2).

Sanger sequencing

The presence of the identified variation was verified by Sanger sequencing of PLCZ1 exon 13. Primers were as followed: PLCZ1_14F: TCAATGTTTGTGGGAGCTGA and PLCZ1_14R: GGACATAATGGAGAAAACCCTTG. Thirty-five cycles of polymerase chain reaction amplification were carried out with an hybridization temperature of 60°C. Sequencing reactions were carried out with BigDye Terminator v3.1 (Applied Biosystems). Sequence analysis were carried out on ABI 3130XL (Applied Biosystems).

Primary antibodies

Anti-human acrosin and PAWP antibodies were from Sigma-Aldrich and Proteintech, respectively; anti-PLCZ1 antibodies were raised against a 15-mer peptide sequence (305KETHERKGSDKRGDN319) of the human PLCZ1 (7), affinity purified and stored at a concentration of 1 µg/µl and used at 1/100 for IF and 1/1000 for WB.

Western blotting

WB was carried out as described by our laboratory (11). Briefly, sperm were first washed in phosphate-buffered saline (PBS) and resuspended in Laemmli sample buffer and boiled. Protein extracts equivalent to 1–2 × 10^6 sperm were loaded per lane into 4–20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and resolved proteins were transferred onto PVDF membranes. The membranes were blocked and incubated...
overnight with anti-PLCZ1 Ab (1/1000) and next with horseradish peroxidase labeled secondary Ab (1 h). Immunoreactivity was detected using chemiluminescence detection kit reagents and a Chimidoc™ Station (Bio-Rad).

Immuno-fluorescence

IF was carried out as described by our laboratory (11). Sperm were fixed with 4% paraformaldehyde, washed in PBS, and spotted onto poly-L-lysine precoated slides. Sperm were then permeabilized with 0.1% (v/v) Triton X-100. Slides were then blocked in 5% normal goat serum–Dulbecco’s PBS (DPBS) (GIBCO, Invitrogen) and incubated overnight at 4°C with primary antibodies. Washes were performed with 0.1% (v/v) Tween 20–DPBS, followed by 1 h incubation with secondary Ab (1/400). Samples were counterstained with Hoechst 33342 and mounted with DAKO mounting media (Life Technology). Fluorescence images were captured with a confocal microscope (Zeiss LSM 710).

Generation of constructs and preparation of cRNA

Human and mouse PLCZ1 constructs were kind gifts from Dr K. Fukami (Tokyo University of Pharmacy and Life Science, Japan) and Dr K. Jones (University of Southampton, UK), respectively. WT h and mPLCZ1-venus sequences were subcloned into a pcDNA6/Myc-His B (Invitrogen) between EcoRI and XbaI.
restrictions sites. hPLCZ1-Ile489Phe and mPlcz1 Ile527Phe were generated by substituting Ile to Phe using the Gibson Assembly Cloning Kit (New England Bio Labs), as previously reported (50). All constructs were finally sequenced. pDsRed2-ER was kindly provided by Dr M Trebak (Penn State Hershey College of Medicine, PA, USA). The ER-targeting sequence of calreticulin, DsRed2 and the KDEL ER retention sequence were ligated to pcDNA6/Myc-His B. Plasmids were linearized outside of the coding region with PmeI and in vitro transcribed using mMESSAGE/mMACHINE T7 Kit (Ambion). Poly-A tail was added to the mRNAs using a Tailing Kit (Ambion).

**Confocal microscopy of fluorescent-PLCZ1**

Live-cell images of oocytes and zygotes expressing fluorescently tagged proteins were captured with a confocal laser-scanning microscope (LSM 510 META, Carl Zeiss) using a 63 × 1.4 numerical aperture oil-immersion objective lens. Images were reconstructed using the LSM software (Carl Zeiss). Oocytes were maintained in HCZB medium and those expressing Venus-hPLCZ1 and DsRed-ER proteins were imaged at the GV stage, whereas expression of Venus-mPlcz1 and DsRed-ER proteins was imaged in PN stage zygotes.

**Ca²⁺ monitoring**

Ca²⁺ monitoring was carried out as described by our laboratory (7). Briefly, mouse oocytes were loaded with fura-2-AM (molecular probes) prior to injecting the cRNAs, after which they were transferred into a monitoring dish containing 50 µl drops of TL-HEPES medium under mineral oil. Excitation wavelengths of 340/380 nm were alternated using a filter wheel (Ludl Electronic

---

**Figure 8.** Molecular dynamic simulation of the effect of the Ile489Phe mutation on the conformation of PLCZ1. (A) The site of the Ile489Phe mutation is located at the interface of C2 and EF-hand domains of PLCZ1 (gray box) (B and C) Enlargement of the red/blue boxes for WT and mutant PLCZ1. As suggested by molecule dynamics simulation, the mutation results in a displacement of the surrounding C2 residues (Y582, F601, Y603 and R487) by the larger side chain of Phe. This reorganisation, in turn, leads to novel contacts between C2 and EF2 hand via persistent hydrophobic (Phe489–Ile76) and H-bonding (Tyr582–Tyr80) side-chain interactions, which shifts the entire EF-hand domain toward C2 by an ~1.5 Å by the end of the 1.2-ns simulation. (D) The molecular surfaces of WT and mutant PLCZ1 in the vicinity of the 489 residue, demonstrating the formation of a novel hydrophobic sub-site at the C2/EF-hand junction. The basic, acidic hydrophobic and polar neutral residues shown in blue, red and cyan, respectively.
residues 303 and 345 to recreate a contiguous mode. A single-chain, liganded model, comprising the residues 64–303 and 345–608, was then built by the energy-based algorithm in Prime to construct and refine non-identical residues and loops with deletions and insertions.

**Molecular dynamics simulations**

Both the resulting complex and pre-minimized I489F mutant were subjected to an unconstrained 1.2 ns, molecular dynamics procedure within Desmond (version 4.0, D. E. Shaw Research & Schrödinger, LLC). An NPT ensemble was built at 300 K and 1 atm with the neutralized (by 10 Cl− ions) system and further Na+/Cl− ions to simulate 150 mm concentration in an explicit SPC solvent model. The interactions that both I489 and the corresponding phenylalanine were participating throughout the simulations were identified using the simulated interaction diagram routine within Desmond. Topological changes were detected using simulated event analysis program by monitoring the Cα(I489)–Cα(489) and Cα(I489)–Cα(489) distances and root mean square fluctuations as a function of simulation time. The mutant structure from the final frame was modified back to contain I489, and a simulation under the identical conditions was conducted to ascertain the persistence of the mutant’s conformation.

**Supplementary Material**

Supplementary Material is available at HMG online.

**Authors’ Contributions**

R.Z., L.H. and C.T. identified patients, J.E., S.Y., H.C.L. and G.M. performed research; C.C., T.K., Z.K., N.T.-M. contributed to genetic analyses; S.N.S. performed PLCZ1 structure analyses; R.F., P.F.R. and C.A. designed research, analyzed data and wrote the paper.

**Acknowledgements**

We thank S. Crouzy (CEA Grenoble) for valuable discussions.

**Conflict of Interest statement.** None declared.

**Funding**

This work was supported by following grants: ANR Genopat 2009, project ICG21 to P.R. and C.A. and NIH R01 HD051872 to R.A.F.

**References**


